Your browser doesn't support javascript.
loading
Fragmentation of care in breast cancer: greater than the sum of its parts.
Freeman, Hadley D; Burke, Linnea C; Humphrey, Ja'Neil G; Wilbers, Ashley J; Vora, Halley; Khorfan, Rhami; Solomon, Naveenraj L; Namm, Jukes P; Ji, Liang; Lum, Sharon S.
Afiliação
  • Freeman HD; Division of Surgical Oncology, Department of Surgery, Loma Linda University, Loma Linda, CA, USA.
  • Burke LC; Division of Surgical Oncology, Department of Surgery, Loma Linda University, Loma Linda, CA, USA.
  • Humphrey JG; Division of Surgical Oncology, Department of Surgery, Loma Linda University, Loma Linda, CA, USA.
  • Wilbers AJ; Division of Breast Surgery, Department of Surgery, Washington University, St. Louis, MO, USA.
  • Vora H; Division of Surgical Oncology, Department of Surgery, Loma Linda University, Loma Linda, CA, USA.
  • Khorfan R; Division of Surgical Oncology, Department of Surgery, Loma Linda University, Loma Linda, CA, USA.
  • Solomon NL; Division of Surgical Oncology, Department of Surgery, Loma Linda University, Loma Linda, CA, USA.
  • Namm JP; Division of Surgical Oncology, Department of Surgery, Loma Linda University, Loma Linda, CA, USA.
  • Ji L; Division of Surgical Oncology, Department of Surgery, Loma Linda University, Loma Linda, CA, USA.
  • Lum SS; Division of Surgical Oncology, Department of Surgery, Loma Linda University, Loma Linda, CA, USA. slum@llu.edu.
Breast Cancer Res Treat ; 208(3): 511-521, 2024 Dec.
Article em En | MEDLINE | ID: mdl-39096403
ABSTRACT

INTRODUCTION:

Fragmentation of care (FC, the receipt of care at > 1 institution) has been shown to negatively impact cancer outcomes. Given the multimodal nature of breast cancer treatment, we sought to identify factors associated with FC and its effects on survival of breast cancer patients.

METHODS:

A retrospective analysis was performed of surgically treated, stage I-III breast cancer patients in the 2004-2020 National Cancer Database, excluding neoadjuvant therapy recipients. Patients were stratified into two groups FC or non-FC care. Treatment delay was defined as definitive surgery > 60 days after diagnosis. Multivariable logistic regression was performed to identify factors predictive of FC, and survival was compared using Kaplan-Meier and multivariable Cox proportional hazards methods.

RESULTS:

Of the 531,644 patients identified, 340,297 (64.0%) received FC. After adjustment, FC (OR 1.27, 95% CI 1.25-1.29) was independently associated with treatment delay. Factors predictive of FC included Hispanic ethnicity (OR 1.04, 95% CI 1.01-1.07), treatment at comprehensive community cancer programs (OR 1.06, 95% CI 1.03-1.08) and integrated network cancer programs (OR 1.55, 95% CI 1.51-1.59), AJCC stage II (OR 1.06, 95% CI 1.05-1.07) and stage III tumors (OR 1.06, 95% CI 1.02-1.10), and HR + /HER2 + tumors (OR 1.05, 95% CI 1.02-1.07). Treatment delay was independently associated with increased risk of mortality (HR 1.23, 95% CI 1.20-1.26), whereas FC (HR 0.87, 95% CI 0.86-0.88) showed survival benefit.

CONCLUSIONS:

While treatment delay negatively impacts survival in breast cancer patients, our findings suggest FC could be a marker for multispecialty care that may mitigate some of these effects.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Estadiamento de Neoplasias Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Estadiamento de Neoplasias Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article